Neurocrine biosciences provides update on erudite™ phase 2 data for luvadaxistat in adults with cognitive impairment associated with schizophrenia

Second phase 2 study for luvadaxistat fails to meet primary endpoint as potential treatment for cognitive impairment associated with schizophrenia results confounded by variability in cognition measures across population studied and potential imbalance in baseline characteristics of enrolled subjects neurocrine biosciences to focus resources on phase 3 clinical development of nbi-1117568 for schizophrenia and nbi-1065845 for major depressive disorder san diego , sept. 12, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that its erudite™ phase 2 clinical study of investigational compound luvadaxistat (nbi-1065844) failed to meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia.
NBIX Ratings Summary
NBIX Quant Ranking